V. Tomati , V. Capurro , E. Pesce , C. Pastorino , F. Cresta , M. Lena , A. Dighero , A. Mantero , M. Ambroni , L. Claut , V. Daccò , C. Castellani , R. Bocciardi , N. Pedemonte
{"title":"WS13.01Characterization of two novel F508del-CFTR complex alleles and their impact on drug responsiveness","authors":"V. Tomati , V. Capurro , E. Pesce , C. Pastorino , F. Cresta , M. Lena , A. Dighero , A. Mantero , M. Ambroni , L. Claut , V. Daccò , C. Castellani , R. Bocciardi , N. Pedemonte","doi":"10.1016/j.jcf.2025.03.564","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>In cystic fibrosis (CF), a complete and correct genetic diagnosis is essential for appropriate therapeutic intervention with CFTR modulating drugs. The triple combination of modulators Elexacaftor, Tezacaftor, and Ivacaftor (ETI) successfully overcome molecular defects of the most frequent variant F508del-CFTR. In this scenario, complex alleles of F508del-CFTR can modify both clinical manifestations and the response to treatment. Indeed, each variant may impact on the structure, folding and activity of the CFTR channel [doi: 10.3390/ijms23063175]. In the frame of a large theratyping project of the Italian CF population, we recruited two unrelated CF patients, compound heterozygous for F508del and a minimal function variant, who were referred as having limited or negligible beneficial effects following treatment with ETI.</div></div><div><h3>Methods</h3><div>We performed molecular, functional and biochemical studies on primary cultures of nasal epithelial cells isolated from patients with CF (pwCF) and on immortalized bronchial cells.</div></div><div><h3>Results</h3><div><em>Ex vivo</em> functional studies on patient-derived nasal epithelia confirmed the lack of response to ETI. In-depth molecular characterization highlighted the presence of additional amino acid substitutions <em>in cis</em> with the F508del variant. The first patient carried a rare poorly characterized variant, while the second patient carried a variant not listed in any database. The double mutant CFTR proteins produced by the complex alleles display reduced activity with negligible rescue by CFTR modulators.</div></div><div><h3>Conclusion</h3><div>This study suggests that in pwCF carrying F508del variant and not responding to modulators, the genotype should be re-evaluated in search of possible complex alleles; it also provides new information regarding poorly or not yet described CFTR variants.</div><div>Supported by The Italian Ministry of Health (PNRR-MR1-2023-12378412), CFF (PEDEMO20G0), FFC Ricerca (FFC#10/2021, “Kaftrio nella vita reale – substudy 1”).</div></div>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":"24 ","pages":"Page S25"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569199325006605","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
In cystic fibrosis (CF), a complete and correct genetic diagnosis is essential for appropriate therapeutic intervention with CFTR modulating drugs. The triple combination of modulators Elexacaftor, Tezacaftor, and Ivacaftor (ETI) successfully overcome molecular defects of the most frequent variant F508del-CFTR. In this scenario, complex alleles of F508del-CFTR can modify both clinical manifestations and the response to treatment. Indeed, each variant may impact on the structure, folding and activity of the CFTR channel [doi: 10.3390/ijms23063175]. In the frame of a large theratyping project of the Italian CF population, we recruited two unrelated CF patients, compound heterozygous for F508del and a minimal function variant, who were referred as having limited or negligible beneficial effects following treatment with ETI.
Methods
We performed molecular, functional and biochemical studies on primary cultures of nasal epithelial cells isolated from patients with CF (pwCF) and on immortalized bronchial cells.
Results
Ex vivo functional studies on patient-derived nasal epithelia confirmed the lack of response to ETI. In-depth molecular characterization highlighted the presence of additional amino acid substitutions in cis with the F508del variant. The first patient carried a rare poorly characterized variant, while the second patient carried a variant not listed in any database. The double mutant CFTR proteins produced by the complex alleles display reduced activity with negligible rescue by CFTR modulators.
Conclusion
This study suggests that in pwCF carrying F508del variant and not responding to modulators, the genotype should be re-evaluated in search of possible complex alleles; it also provides new information regarding poorly or not yet described CFTR variants.
Supported by The Italian Ministry of Health (PNRR-MR1-2023-12378412), CFF (PEDEMO20G0), FFC Ricerca (FFC#10/2021, “Kaftrio nella vita reale – substudy 1”).
目的在囊性纤维化(CF)中,完整和正确的基因诊断对于使用CFTR调节药物进行适当的治疗干预至关重要。该调制器Elexacaftor、Tezacaftor和Ivacaftor (ETI)的三重组合成功克服了最常见的F508del-CFTR变体的分子缺陷。在这种情况下,F508del-CFTR的复杂等位基因可以改变临床表现和对治疗的反应。事实上,每种变异都可能影响CFTR通道的结构、折叠和活性[doi: 10.3390/ijms23063175]。在意大利CF人群的大型治疗分型项目框架内,我们招募了两名不相关的CF患者,F508del的复合杂合和最小功能变体,他们被认为在接受ETI治疗后具有有限或可忽略的有益效果。方法对CF患者鼻上皮细胞(pwCF)原代培养和永生化支气管细胞进行分子、功能和生化研究。结果患者源性鼻上皮的体内功能研究证实了对ETI缺乏反应。深入的分子表征强调了F508del变体在cis中存在额外的氨基酸取代。第一位患者携带一种罕见的特征不明显的变异,而第二位患者携带一种未在任何数据库中列出的变异。复合等位基因产生的双突变CFTR蛋白显示活性降低,CFTR调节剂的挽救作用可以忽略不计。结论携带F508del变异且对调节因子无应答的pwCF应重新评估基因型,寻找可能的复合等位基因;它还提供了关于缺乏或尚未描述的CFTR变体的新信息。由意大利卫生部(PNRR-MR1-2023-12378412)、CFF (PEDEMO20G0)、FFC Ricerca (ffc# 10/2021,“Kaftrio nella vita reale -子研究1”)支持。
期刊介绍:
The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.